Sandoz recruits first patient in clinical study for proposed biosimilar denosumab in osteoporosis
The study aims to confirm that the biosimilar matches the reference medicine in terms of pharmacokinetics, efficacy, safety, and immunogenicity in patients with postmenopausal osteoporosis. Denosumab is indicated